<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00462748</url>
  </required_header>
  <id_info>
    <org_study_id>0653A-121</org_study_id>
    <secondary_id>MK0653A-121</secondary_id>
    <secondary_id>2007_013</secondary_id>
    <nct_id>NCT00462748</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)</brief_title>
  <official_title>A MC, DB, Rand, Study to Evaluate Efficacy, Safety and Tolerability of Eze/Simva 10/40 mg, Atorva 40 mg, Rosuva 10 mg in Achieving LDL-C &lt;2 mmol/l in Pts With CVD...on Simva 40 mg With LDL-C ³2 mmol/l</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      To evaluate the percentage of patients with either established cardiovascular disease (CVD),
      at &quot;high risk&quot; of developing CVD or with diabetes who are on simvastatin 40mg, with fasting
      LDL-C &gt; 2mmol/l, who are able to attain the recommended LDL-C target of &lt; 2mmol/l following 6
      weeks treatment with either ezetimibe/simvastatin 10/40mg, atorvastatin 40mg or rosuvastatin
      10mg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Achieving a Target of Fasting LDL-C of &lt;2mmol/l at Study End</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Fasting LDL-C was the primary efficacy variable. The primary efficacy analysis was based on the proportion of patients achieving a target of &lt;2mmol/l in fasting LDL-C at study end.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">786</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1: Drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2: Active comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 3: Active comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe (+) simvastatin</intervention_name>
    <description>ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally, cholesterol lowering medication.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>MK0653A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: atorvastatin</intervention_name>
    <description>atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally</description>
    <arm_group_label>2</arm_group_label>
    <other_name>atorvastatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: rosuvastatin</intervention_name>
    <description>rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>rosuvastatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient Is Male Or Female And Aged Over 18

          -  Patient Provides Written Informed Consent

          -  Patient Has A Fasting Ldl-C Level &gt;2mmol/L At Both Visit 1 And Again At Visit 2

          -  Patient Has Established Cvd, Diabetes Or At &quot;High Risk&quot; Of Cvd (&gt;20 % Risk Over 10
             Years, Framingham Scale)

          -  Patient Has Taken Simvastatin 40mg Continuously For The Past 6 Weeks

          -  Patient Has A Fasting Triglyceride Level Of &lt;3.7mmol/L

          -  Patient Has Hba1c &lt;9% At Visit 1

          -  Patient Is 75% Compliant With Medication Between Visit 1 And Visit 2

        Exclusion Criteria:

          -  Patient Is Hypersensitive To Any Of The Study Medications Or Their Components

          -  Patient Has A History Of, Or Active Liver Disease (Persistent Elevation Of Alt / Ast
             (&gt;3xuln)

          -  Patient Is Pregnant, Lactating, Or A Female Patient Of Childbearing Potential Not
             Using Adequate Contraception

          -  Patient Has Severe Renal Impairment: Creatinine Clearance &lt;30ml/Min (Cockcroft-Gault
             Equation) (In Patients With Moderate Renal Impairment: &lt;60ml/Min, The Dose Of
             Rosuvastatin Will Be 5mg In Line With The Spc)

          -  Patient Has Uncontrolled Endocrine Or Metabolic Disease Known To Influence Serum
             Lipids Or Lipoproteins (I.E. Secondary Causes Of Hyperlipidaemia Such As
             Hypothyroidism Or Hyperthyroidism)

          -  Patient Has A Recent History Of, Or Current, Alcohol Abuse

          -  Patient Has Ck &gt;10 X Uln At Visit 1 Or Visit 2

          -  Patient Has Fasting Ldl-C &gt;4.2mmol/L

          -  Patient Has Any Acute Or Serious Condition, Or History Suggestive Of Myopathy Or
             Predisposing To The Development Of Renal Failure Secondary To Rhabdomyolysis (E.G.
             Sepsis, Hypotension, Major Surgery, Trauma, Severe Metabolic, Severe Endocrine And
             Electrolyte Disorders Or Uncontrolled Seizures)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2007</study_first_submitted>
  <study_first_submitted_qc>April 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2007</study_first_posted>
  <results_first_submitted>May 7, 2009</results_first_submitted>
  <results_first_submitted_qc>July 6, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 17, 2009</results_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with diabetes, cardiovascular disease (CVD) or a “high risk” of developing CVD and a fasting LDL-C level of ≥2mmol/l, having been on simvastatin 40mg for 6 weeks were assigned to 10/40 mg ezetimibe/simvastatin; 40 mg atorvastatin; 10 mg rosuvastatin (5 mg in elderly/Asian patients (in line with UK SPC)) between 27/03/2007 and 31/03/2008</recruitment_details>
      <pre_assignment_details>All patients were subjected to a 6 week run-in period on open label 40 mg simvastatin to stabilise their LDL-C levels. Patients whose LDL-C at the end of this period was below 2.0 mmol/l or who were &lt;75% compliant with run-in medication, were excluded from the study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ezetimibe/Simvastatin</title>
          <description>ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally</description>
        </group>
        <group group_id="P2">
          <title>Atorvostatin</title>
          <description>atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally</description>
        </group>
        <group group_id="P3">
          <title>Rosuvastatin</title>
          <description>rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="261"/>
                <participants group_id="P2" count="263"/>
                <participants group_id="P3" count="262"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
                <participants group_id="P2" count="252"/>
                <participants group_id="P3" count="251"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued after 41 days Rx</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ezetimibe/Simvastatin</title>
          <description>ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally</description>
        </group>
        <group group_id="B2">
          <title>Atorvostatin</title>
          <description>atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally</description>
        </group>
        <group group_id="B3">
          <title>Rosuvastatin</title>
          <description>rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="261"/>
            <count group_id="B2" value="263"/>
            <count group_id="B3" value="262"/>
            <count group_id="B4" value="786"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.7" spread="8.65"/>
                    <measurement group_id="B2" value="64.2" spread="8.44"/>
                    <measurement group_id="B3" value="63.9" spread="8.61"/>
                    <measurement group_id="B4" value="64.3" spread="8.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="187"/>
                    <measurement group_id="B3" value="195"/>
                    <measurement group_id="B4" value="567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="263"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="178"/>
                    <measurement group_id="B4" value="523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="257"/>
                    <measurement group_id="B4" value="772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Achieving a Target of Fasting LDL-C of &lt;2mmol/l at Study End</title>
        <description>Fasting LDL-C was the primary efficacy variable. The primary efficacy analysis was based on the proportion of patients achieving a target of &lt;2mmol/l in fasting LDL-C at study end.</description>
        <time_frame>6 Weeks</time_frame>
        <population>The Full Analysis Set (FAS) all patients who were:
Randomised
Took at least one dose of double-blind medication
Had a baseline measurement of efficacy
Had a post-baseline measurement of efficacy
Patients were analysed according to the treatment group they were randomised, regardless of the treatment they received</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally</description>
          </group>
          <group group_id="O2">
            <title>Atorvostatin</title>
            <description>atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving a Target of Fasting LDL-C of &lt;2mmol/l at Study End</title>
          <description>Fasting LDL-C was the primary efficacy variable. The primary efficacy analysis was based on the proportion of patients achieving a target of &lt;2mmol/l in fasting LDL-C at study end.</description>
          <population>The Full Analysis Set (FAS) all patients who were:
Randomised
Took at least one dose of double-blind medication
Had a baseline measurement of efficacy
Had a post-baseline measurement of efficacy
Patients were analysed according to the treatment group they were randomised, regardless of the treatment they received</population>
          <units>Percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="259"/>
                <count group_id="O3" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4"/>
                    <measurement group_id="O2" value="36.3"/>
                    <measurement group_id="O3" value="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ho is no difference in proportion achieving the target of LDL-C &lt; 2mmol/l.. 240 patients per group give a power of at least 85% to detect a 15% difference in this proportion, assuming the percentage decrease from baseline in LDL-C was 25% in the E/S group and 15% in the two comparator groups. A two-sided 0.025 test to allow for multiple comparisons was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Hochberg’s FDR was used to power the study; the power was based on a two-sided p value of 0.025.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The logistic regression model included terms for treatment and stratum; treatment by stratum interaction was assessed.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ho is no difference in proportion achieving the target of LDL-C &lt; 2mmol/l.. 240 patients per group give a power of at least 85% to detect a 15% difference in this proportion, assuming the percentage decrease from baseline in LDL-C was 25% in the E/S group and 15% in the two comparator groups. A two-sided 0.025 test to allow for multiple comparisons was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Hochberg’s FDR was used to power the study; the power was based on a two-sided p value of 0.025.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The logistic regression model included terms for treatment and stratum; treatment by stratum interaction was assessed.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ezetimibe/Simvastatin</title>
          <description>ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally</description>
        </group>
        <group group_id="E2">
          <title>Atorvostatin</title>
          <description>atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally</description>
        </group>
        <group group_id="E3">
          <title>Rosuvastatin</title>
          <description>rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Medora V10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4"/>
                <counts group_id="E2" subjects_affected="2"/>
                <counts group_id="E3" subjects_affected="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic regurgitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Oesophageal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erthematous rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Areterial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>Medora V10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6"/>
                <counts group_id="E2" subjects_affected="1"/>
                <counts group_id="E3" subjects_affected="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

